- Home
- RXST vs INBX Comparison
RXST vs INBX Comparison
Compare RXST & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RXST | INBX |
|---|---|---|
| Founded | 1997 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 417.3M | 430.2M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | RXST | INBX |
|---|---|---|
| Price | $12.72 | $89.43 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 11 | 2 |
| Target Price | ★ $11.30 | N/A |
| AVG Volume (30 Days) | ★ 875.0K | 261.6K |
| Earning Date | 11-05-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $142,085,000.00 | $1,400,000.00 |
| Revenue This Year | N/A | $563.00 |
| Revenue Next Year | $4.18 | $230.77 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 10.75 | N/A |
| 52 Week Low | $6.32 | $10.81 |
| 52 Week High | $44.22 | $90.58 |
Technical Indicators
Market Signals| Indicator | RXST | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 75.78 | 70.37 |
| Support Level | $11.20 | $78.82 |
| Resistance Level | $10.12 | $86.23 |
| Average True Range (ATR) | 0.70 | 5.66 |
| MACD | 0.23 | -0.72 |
| Stochastic Oscillator | 89.45 | 97.05 |
Price Performance
Historical ComparisonAbout RXST RxSight Inc.
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.